Syndax Pharmaceuticals Inc - Common Stock (SNDX)
CUSIP: 87164F105
Q4 2022 13F Holders as of 31 Dec 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 86,727,396
- Total 13F shares
- 71,468,832
- Share change
- +10,250,881
- Total reported value
- $1,818,847,118
- Put/Call ratio
- 96%
- Price per share
- $25.45
- Number of holders
- 159
- Value change
- +$262,720,878
- Number of buys
- 96
- Number of sells
- 47
Quarterly Holders Quick Answers
What is CUSIP 87164F105?
CUSIP 87164F105 identifies SNDX - Syndax Pharmaceuticals Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 87164F105:
Top shareholders of SNDX - Syndax Pharmaceuticals Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avidity Partners Management LP |
13F
|
Company |
6.4%
|
5,586,900
|
$134,253,000 | — | 30 Sep 2022 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
5.1%
|
4,387,440
|
$105,429,000 | — | 30 Sep 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
4.8%
|
4,139,617
|
$99,476,000 | — | 30 Sep 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
3.9%
|
3,412,838
|
$82,010,000 | — | 30 Sep 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.2%
|
2,802,299
|
$67,339,000 | — | 30 Sep 2022 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
2,617,437
|
$62,897,000 | — | 30 Sep 2022 | |
| Kynam Capital Management, LP |
13F
|
Company |
2.6%
|
2,272,915
|
$54,618,000 | — | 30 Sep 2022 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
2.6%
|
2,222,222
|
$53,400,000 | — | 30 Sep 2022 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
2.3%
|
2,006,500
|
$48,216,000 | — | 30 Sep 2022 | |
| BVF INC/IL |
13F
|
Company |
2.1%
|
1,798,085
|
$43,208,000 | — | 30 Sep 2022 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.9%
|
1,649,795
|
$39,645,000 | — | 30 Sep 2022 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
1.6%
|
1,375,428
|
$33,052,000 | — | 30 Sep 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.6%
|
1,366,771
|
$32,844,000 | — | 30 Sep 2022 | |
| PFM Health Sciences, LP |
13F
|
Company |
1.5%
|
1,289,073
|
$30,976,000 | — | 30 Sep 2022 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.4%
|
1,250,000
|
$30,038,000 | — | 30 Sep 2022 | |
| Eversept Partners, LP |
13F
|
Company |
1.4%
|
1,211,434
|
$29,110,759 | — | 30 Sep 2022 | |
| 683 Capital Management, LLC |
13F
|
Company |
1.3%
|
1,130,000
|
$27,154,000 | — | 30 Sep 2022 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.3%
|
1,122,452
|
$26,974,000 | — | 30 Sep 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.3%
|
1,085,142
|
$26,076,000 | — | 30 Sep 2022 | |
| Aisling Capital Management LP |
13F
|
Company |
1.2%
|
1,025,000
|
$24,631,000 | — | 30 Sep 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
968,129
|
$23,264,000 | — | 30 Sep 2022 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
1.1%
|
923,226
|
$22,186,000 | — | 30 Sep 2022 | |
| HealthCor Management, L.P. |
13F
|
Company |
0.99%
|
859,240
|
$20,648,000 | — | 30 Sep 2022 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.95%
|
822,696
|
$19,769,000 | — | 30 Sep 2022 | |
| Woodline Partners LP |
13F
|
Company |
0.91%
|
789,273
|
$18,966,000 | — | 30 Sep 2022 | |
| Commodore Capital LP |
13F
|
Company |
0.85%
|
738,110
|
$17,737,000 | — | 30 Sep 2022 | |
| Foresite Capital Management IV, LLC |
13F
|
Company |
0.8%
|
690,000
|
$16,581,000 | — | 30 Sep 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.71%
|
616,251
|
$14,808,000 | — | 30 Sep 2022 | |
| Palo Alto Investors LP |
13F
|
Company |
0.71%
|
612,600
|
$14,721,000 | — | 30 Sep 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.66%
|
568,081
|
$13,651,000 | — | 30 Sep 2022 | |
| CITIGROUP INC |
13F
|
Company |
0.61%
|
530,972
|
$12,759,000 | — | 30 Sep 2022 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.61%
|
525,002
|
$12,616,000 | — | 30 Sep 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.58%
|
503,962
|
$12,111,000 | — | 30 Sep 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.44%
|
385,121
|
$9,255,000 | — | 30 Sep 2022 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.43%
|
371,752
|
$8,933,000 | — | 30 Sep 2022 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.41%
|
355,487
|
$8,542,000 | — | 30 Sep 2022 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.39%
|
334,963
|
$8,049,000 | — | 30 Sep 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.37%
|
324,614
|
$7,800,000 | — | 30 Sep 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.35%
|
302,125
|
$7,260,000 | — | 30 Sep 2022 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
285,532
|
$6,861,000 | — | 30 Sep 2022 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.32%
|
276,731
|
$6,650,000 | — | 30 Sep 2022 | |
| BARCLAYS PLC |
13F
|
Company |
0.32%
|
275,759
|
$6,626,000 | — | 30 Sep 2022 | |
| Steve M. Sabus |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
220,000
|
$5,685,614 | — | 05 Dec 2022 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.24%
|
211,368
|
$5,080,000 | — | 30 Sep 2022 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.23%
|
200,000
|
$4,806,000 | — | 30 Sep 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.22%
|
189,194
|
$4,547,000 | — | 30 Sep 2022 | |
| NORGES BANK |
13F
|
Company |
0.22%
|
188,200
|
$4,522,446 | — | 30 Sep 2022 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.21%
|
180,000
|
$4,325,000 | — | 30 Sep 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.19%
|
165,877
|
$3,986,000 | — | 30 Sep 2022 | |
| FMR LLC |
13F
|
Company |
0.19%
|
165,873
|
$3,986,000 | — | 30 Sep 2022 |
Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock (SNDX) as of Q4 2022
As of 31 Dec 2022,
Syndax Pharmaceuticals Inc - Common Stock (SNDX) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,468,832 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Avidity Partners Management LP, BlackRock Inc., Frazier Life Sciences Management, L.P., STATE STREET CORP, VANGUARD GROUP INC, Avoro Capital Advisors LLC, Kynam Capital Management, LP, JENNISON ASSOCIATES LLC, and ORBIMED ADVISORS LLC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2022 vs Q3 2022 Across Filers
Q3 2022 holders
136
Q4 2022 holders
159
Holder diff
23
| Investor | Q3 2022 Shares | Q4 2022 Shares | Share Diff | Share Chg % | Q3 2022 Value $ | Q4 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.